Molecular breast imaging is an accurate and cost-effective supplemental screening tool

August 17, 2015

Molecular breast imaging (MBI) as a secondary screening tool for women with dense breasts is more cost-effective than screening with mammography alone, according to a new Mayo Clinic study. The industry is searching for ways to improve cancer detection in dense breasts and research like this may hold the answer. 

"In the past, the market has struggled to meet the needs of the 45 percent of women with dense breast tissue," Philip Croxford, president and CEO of Gamma Medica Inc., told HCB News. "This study reinforces that MBI technology is a highly effective tool for secondary breast cancer screening." 

Read the full story.